思春期早発症治療の世界市場：2024年～2031年

概要

世界の思春期早発症治療市場は、2023年に17億米ドルに達し、2024-2031年の予測期間中にCAGR 7.6％で成長し、2031年には31億米ドルに達すると予測されています。

思春期早発症とは、小児における思春期の早期発症と定義され、男児では9歳、女児では8歳以前に第二次性徴が発現することを特徴とします。

症状は患者の性別によって異なり、女児では乳房の発育、月経、急速な成長などが、男児では睾丸や陰茎の肥大、声の深まりなどがみられます。さらに、他の一般的な適応症には骨の成長が含まれ、これは成人身長の低さにつながる可能性もあります。

市場力学：

促進要因

研究開発と製品認可の増加

世界の思春期早発症治療市場は、最近の様々な研究開発により大きな成長を遂げています。思春期早発症は通常、病歴や臨床所見、画像所見に基づいて診断されます。また、思春期早発症を治療するための先進的な研究開発がこの市場の成長を後押ししています。

シュプリンガー・ジャーナル誌によると、2022年1月に発表された「Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty（中枢性思春期早発症の女児におけるゴナドトロピン放出ホルモン作動薬単剤療法と成長ホルモンとの併用療法が最終的な成人身長に及ぼす影響）」と題された論文によると、GnRHaは男女ともにCPPの標準的な治療法です。性ホルモンの分泌を抑制して思春期を遅らせ、急激な骨融合を抑制して最終的な成人身長を成長ホルモンの範囲内にすることが知られています。

さらに、業界の主要企業は、この市場成長の原動力となる革新的な医薬品を発売しました。例えば、BDR Pharmaceuticalsは2022年2月、前立腺がん患者向けに「BDENZA」のブランド名で160mgの「ENZALUTAMIDE」を発売しました。この薬はこれまで40mgと80mgの2種類があり、患者は承認用量に従って1日2錠を服用する必要があった。

阻害要因

高額な治療費、薬物治療に伴う副作用、人々の認識不足、厳しい規制当局の承認などの要因が、市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 研究開発と製品認可の増加
    • ホルモン疾患の増加
  • 抑制要因
    • 治療費の高騰
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 タイプ別

• 中枢性思春期早発症
• 末梢性思春期早発症

第7章 治療別

• 薬物療法
  • 酢酸リュープロリド
  • トリプトレリン
  • 酢酸ヒストレリン
  • ナファレリン
  • その他
• 手術
• その他

第8章 エンドユーザー別

• 病院・クリニック
• 外来手術センター
• 在宅医療
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第11章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Bachem A.G
• Aspen API
• Sanofi S.A
• Piramal Solutions
• Anygen Co. Ltd
• Sigma Aldrich
• Ferring Pharmaceuticals
• LGM Pharma
• AmbioPharm

第12章 付録

Overview

The global precocious puberty treatment market reached US$ 1.7 billion in 2023 and is expected to reach US$ 3.1 billion by 2031 growing with a CAGR of 7.6% during the forecast period 2024-2031.

Precocious puberty is defined as the premature onset of puberty in children, characterized by the development of secondary sexual characteristics before the age of 9 in boys and 8 in girls.

The symptoms vary depending on the patient's gender, girls may experience breast development, menstruation, and rapid growth, while boys might show enlarged testicles and penis, facial hair expansion, and a deepening voice. Additionally, other common indications include bone growth, which might also lead to shorter adult height.

Market Dynamics: Drivers

Increasing Research & Development and Product Approvals

The global precocious puberty treatment market has witnessed significant growth due to various recent research and developments. Precocious puberty is usually diagnosed based on medical history and clinical and imaging findings. Also, advanced research and developments in treating precocious puberty drive this market growth.

According to Springer Journal, an article entitled Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty published in January 2022 states that GnRHa is a standard treatment for CPP in both boys and girls. It is known to suppress the secretion of sex hormones to slow puberty and suppress rapid bone fusion to achieve final adult height within the growth hormone range.

Moreover, key players in the industry launched innovative drugs that would drive this market growth. For instance, in February 2022, BDR Pharmaceuticals launched its brand ENZALUTAMIDE in 160mg with the brand name BDENZA for Prostate Cancer patients. This medicine was previously available in 40mg and 80mg strength for which patients had to consume two tablets a day as per approved dosage.

Restraints

Factors such as the high cost of the treatment, side effects associated with the treatment of drugs, lack of awareness among people, and stringent regulatory approvals, are expected to hamper the market.

Segment Analysis

The global precocious puberty treatment market is segmented based on type, treatment, end-user, and region.

The medications segment accounted for approximately 55.3% of the global precocious puberty treatment market share

The medications segment is expected to hold the largest market share over the forecast period. The rising clinical trials of drugs globally have contributed to the growing demand for precocious puberty treatment.

According to clinicalTrials.gov, in August. 2023, Foresee Pharmaceuticals Co., Ltd. In collaboration with GeneScience Pharmaceuticals Co., Ltd. conducted a clinical trial to evaluate the efficacy, safety, and pharmacokinetics of leuprolide mesylate in subjects with Central Precocious Puberty.

Moreover, key players' ongoing research studies in the treatment of precocious puberty and launching new drugs would drive this market growth. For instance, in March 2023, Takeda Pharmaceuticals conducted an interventional study of Leuprolide Acetate Depot in children with central precocious puberty. The main aim is to check how leuprolide works to treat central precocious puberty in children.

Also, in March 2022, Accord BioPharma announced the U.S. launch of CAMCEVI (Leuprolide) injection emulsion for the treatment of advanced prostate cancer in adults.

Geographical Analysis

North America accounted for approximately 43.2% of the global precocious puberty market share

North America region is expected to hold the largest market share over the forecast period owing to the rising incidence of precocious puberty, advancements in medical research & technology would drive this market growth.

According to a study published in the Journal of Clinical Endocrinology & Metabolism, in May 2023, the incidence of central precocious puberty in North America has been steadily increasing, with a prevalence of approximately 1 in 5,000 to 1 in 10,000 children. It is estimated that approximately 80% - 90% of CPP cases are idiopathic, especially in females, with a female-to-male ratio of around 20: 1.

Moreover, major key players' presence, well-advanced healthcare system, growing healthcare expenditure, and government support & funding in the development of drugs propel this market growth. For instance, in October 2023, Foresee Pharmaceuticals announced the first patient dosed in the Caspian, phase 3 clinical trial of leuprolide (fp-001) injectable emulsion, 42 mg for the treatment of central precocious puberty patients.

Market Segmentation

By Type

• Central Precocious Puberty
• Peripheral Precocious Puberty

By Treatment

• Medications
  • Leuprolide Acetate
  • Triptorelin
  • Histrelin Acetate
  • Nafarelin
  • Others
• Surgery
• Others

By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the precocious puberty treatment market include Pfizer Inc., Bachem A.G, Aspen API, Sanofi S.A, Piramal Solutions, Anygen Co. Ltd, Sigma Aldrich, Ferring Pharmaceuticals, LGM Pharma, and AmbioPharm among others.

Key Developments

• In April 2024, Foresee Pharmaceuticals Receives a Positive Recommendation from DSMB to Continue the Caspian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Central Precocious Puberty.
• In January 2024, BDR Pharmaceuticals launches BDENZA a prostate cancer drug in oral solution form. The formulation provides an effective dosage form, with fewer side effects in comparison to existing oral dosage forms of enzalutamide.

Why Purchase the Report?

• To visualize the global precocious puberty treatment market segmentation based on type, treatment, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global precocious puberty treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global precocious puberty treatment market report would provide approximately 62 tables, 57 figures, and 181 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Research & Development and Product Approvals
    • 4.1.1.2. Growing Prevalence of Hormonal Disorders
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of the Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Central Precocious Puberty
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Peripheral Precocious Puberty

7. By Treatment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.1.2. Market Attractiveness Index, By Treatment
• 7.2. Medications
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.2.1. Leuprolide Acetate
    • 7.2.2.2. Triptorelin
    • 7.2.2.3. Histrelin Acetate
    • 7.2.2.4. Nafarelin
    • 7.2.2.5. Others
• 7.3. Surgery
• 7.4. Others

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 8.1.2. Market Attractiveness Index, By End-user
• 8.2. Hospitals & Clinics
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Ambulatory Surgical Centers
• 8.4. Home Care
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Product Benchmarking
• 10.3. Company Share Analysis
• 10.4. Key Developments and Strategies

11. Company Profiles

• 11.1. Pfizer Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Bachem A.G
• 11.3. Aspen API
• 11.4. Sanofi S.A
• 11.5. Piramal Solutions
• 11.6. Anygen Co. Ltd
• 11.7. Sigma Aldrich
• 11.8. Ferring Pharmaceuticals
• 11.9. LGM Pharma
• 11.10. AmbioPharm

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us